Lapouméroulie Claudine, Benkerrou Malika, Odièvre Marie Hélène, Ducrocq Rolande, Brun Manuel, Elion Jacques
Haematologica. 2005 Mar;90(3):401-3.
Plasma endothelin-1 (ET-1) is elevated in patients with sickle cell disease (SCD). Hydroxyurea (HU) is the only drug with demonstrated clinical efficacy in SCD. Here we show that treatment with HU results in a decreased concentration of circulating ET-1 which is not correlated with the HU-induced increase in HbF level. Blunting of the ET-1 vasoconstrictive stimulus could contribute to the beneficial effects of HU.
镰状细胞病（SCD）患者的血浆内皮素-1（ET-1）水平升高。羟基脲（HU）是唯一已证明对SCD有临床疗效的药物。在此我们表明，HU治疗可导致循环ET-1浓度降低，这与HU诱导的HbF水平升高无关。ET-1血管收缩刺激的减弱可能有助于HU的有益作用。
